[144] Madrigal Pharmaceuticals, Inc. SEC Filing
Madrigal Pharmaceuticals (MDGL) reported a Form 144 notice for the proposed sale of 4,100 shares of common stock through Morgan Stanley Smith Barney LLC on 08/15/2025. The filing lists an aggregate market value of $1,503,481.48 based on the transaction and shows 22,289,014 shares outstanding for the issuer. The shares were acquired and are being sold on the same date by exercise of options under a registered plan and payment was made in cash. The filer reports nothing to report for securities sold during the past three months and includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Madrigal Pharmaceuticals (MDGL) ha comunicato, tramite un avviso Form 144, l'intenzione di vendere 4.100 azioni ordinarie tramite Morgan Stanley Smith Barney LLC in data 15/08/2025. La documentazione indica un valore di mercato complessivo pari a $1.503.481,48 basato sull'operazione e riporta 22.289.014 azioni in circolazione per l'emittente. Le azioni sono state acquisite e saranno vendute nella medesima data a seguito dell'esercizio di opzioni nell'ambito di un piano registrato, con pagamento effettuato in contanti. Il dichiarante segnala nulla da riportare relativamente a titoli venduti negli ultimi tre mesi e include la consueta attestazione che il venditore non 猫 a conoscenza di informazioni materiali riservate non divulgate.
Madrigal Pharmaceuticals (MDGL) present贸 un aviso Form 144 para la venta propuesta de 4.100 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC el 15/08/2025. El expediente indica un valor de mercado agregado de $1.503.481,48 seg煤n la transacci贸n y muestra 22.289.014 acciones en circulaci贸n del emisor. Las acciones fueron adquiridas y se vender谩n en la misma fecha por el ejercicio de opciones bajo un plan registrado, con pago en efectivo. El presentante informa nada que reportar sobre valores vendidos en los 煤ltimos tres meses e incluye la atestaci贸n est谩ndar de que el vendedor no conoce informaci贸n material adversa no divulgada.
Madrigal Pharmaceuticals (MDGL)電� 鞝滌晥霅� 氤错喌欤� 4,100欤茧ゼ Morgan Stanley Smith Barney LLC毳� 韱淀暣 2025-08-15鞐� 毵り皝頃� 鞓堨爼鞛勳潉 鞎岆Μ電� Form 144 韱奠毳� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊電� 瓯半灅毳� 旮办鞙茧 頃� 齑� 鞁滌灔臧�旃橂ゼ $1,503,481.48搿� 旮办灛頃橁碃 氚滍枆靷潣 鞙犿喌欤检嫕 靾橂ゼ 22,289,014欤茧 響滌嫓頃橁碃 鞛堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 霌彪霅� 瓿勴殟鞐� 霐半ジ 鞓奠厴 頄夓偓搿� 霃欖澕頃� 雮犾鞐� 旆摑霅橃柎 韺愲Г霅橂┌, 雽�旮堨潃 顺勱笀鞙茧 歆�旮夒悩鞐堨姷雼堧嫟. 鞁犼碃鞛愲姅 歆�雮� 靹� 雼� 霃欖晥 毵る弰霅� 歃濌秾鞐� 雽�頃� 氤搓碃頃� 靷暛 鞐嗢潓鞚� 氤搓碃頄堨溂氅�, 毵る弰鞚胳澊 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 頇曥澑靹滊弰 韽暔頃橁碃 鞛堨姷雼堧嫟.
Madrigal Pharmaceuticals (MDGL) a d茅pos茅 un avis Form 144 pour la vente propos茅e de 4 100 actions ordinaires par l'interm茅diaire de Morgan Stanley Smith Barney LLC le 15/08/2025. le dossier indique une valeur de march茅 agr茅g茅e de 1 503 481,48 $ bas茅e sur la transaction et fait 茅tat de 22 289 014 actions en circulation pour l'茅metteur. Les actions ont 茅t茅 acquises et seront vendues 脿 la m锚me date suite 脿 l'exercice d'options dans le cadre d'un plan enregistr茅, le paiement ayant 茅t茅 effectu茅 en 别蝉辫猫肠别蝉. Le d茅clarant indique rien 脿 signaler concernant des titres vendus au cours des trois derniers mois et inclut l'attestation standard selon laquelle le vendeur n'est pas au courant d'informations d茅favorables importantes non divulgu茅es.
Madrigal Pharmaceuticals (MDGL) meldete eine Form 144-Mitteilung 眉ber den geplanten Verkauf von 4.100 Stammaktien 眉ber Morgan Stanley Smith Barney LLC am 15.08.2025. Die Einreichung nennt einen aggregierten Marktwert von $1.503.481,48 basierend auf der Transaktion und weist 22.289.014 ausstehende Aktien des Emittenten aus. Die Aktien wurden erworben und werden am selben Datum durch Aus眉bung von Optionen im Rahmen eines registrierten Plans verkauft; die Zahlung erfolgte in Bargeld. Der Einreicher gibt f眉r in den letzten drei Monaten verkaufte Wertpapiere nichts zu berichten an und enth盲lt die 眉bliche Versicherung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen negativen Informationen bekannt sind.
- None.
- None.
Insights
TL;DR: Routine insider sale following option exercise; small in scale relative to outstanding shares, likely neutral.
The filing documents a sale of 4,100 shares executed through a broker after exercising options under a registered plan and paid in cash. The aggregate value shown is $1,503,481.48 versus 22,289,014 shares outstanding, representing roughly 0.018% of outstanding stock, indicating this is a modest transaction with limited potential impact on market supply or control metrics. The filer states no other sales in the prior three months and makes the standard attestation about undisclosed material adverse information.
TL;DR: Compliance-focused disclosure of an option exercise followed by a sale; appears procedural and compliant with Rule 144.
The notice shows acquisition by exercise of options under a registered plan and immediate proposed sale through an institutional broker, which is consistent with routine secondary-market liquidity events by insiders or option holders. The inclusion of the broker name and the explicit 'nothing to report' for prior three months supports transparency. There are no indications in the filing of any material governance or disclosure issues.
Madrigal Pharmaceuticals (MDGL) ha comunicato, tramite un avviso Form 144, l'intenzione di vendere 4.100 azioni ordinarie tramite Morgan Stanley Smith Barney LLC in data 15/08/2025. La documentazione indica un valore di mercato complessivo pari a $1.503.481,48 basato sull'operazione e riporta 22.289.014 azioni in circolazione per l'emittente. Le azioni sono state acquisite e saranno vendute nella medesima data a seguito dell'esercizio di opzioni nell'ambito di un piano registrato, con pagamento effettuato in contanti. Il dichiarante segnala nulla da riportare relativamente a titoli venduti negli ultimi tre mesi e include la consueta attestazione che il venditore non 猫 a conoscenza di informazioni materiali riservate non divulgate.
Madrigal Pharmaceuticals (MDGL) present贸 un aviso Form 144 para la venta propuesta de 4.100 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC el 15/08/2025. El expediente indica un valor de mercado agregado de $1.503.481,48 seg煤n la transacci贸n y muestra 22.289.014 acciones en circulaci贸n del emisor. Las acciones fueron adquiridas y se vender谩n en la misma fecha por el ejercicio de opciones bajo un plan registrado, con pago en efectivo. El presentante informa nada que reportar sobre valores vendidos en los 煤ltimos tres meses e incluye la atestaci贸n est谩ndar de que el vendedor no conoce informaci贸n material adversa no divulgada.
Madrigal Pharmaceuticals (MDGL)電� 鞝滌晥霅� 氤错喌欤� 4,100欤茧ゼ Morgan Stanley Smith Barney LLC毳� 韱淀暣 2025-08-15鞐� 毵り皝頃� 鞓堨爼鞛勳潉 鞎岆Μ電� Form 144 韱奠毳� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊電� 瓯半灅毳� 旮办鞙茧 頃� 齑� 鞁滌灔臧�旃橂ゼ $1,503,481.48搿� 旮办灛頃橁碃 氚滍枆靷潣 鞙犿喌欤检嫕 靾橂ゼ 22,289,014欤茧 響滌嫓頃橁碃 鞛堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 霌彪霅� 瓿勴殟鞐� 霐半ジ 鞓奠厴 頄夓偓搿� 霃欖澕頃� 雮犾鞐� 旆摑霅橃柎 韺愲Г霅橂┌, 雽�旮堨潃 顺勱笀鞙茧 歆�旮夒悩鞐堨姷雼堧嫟. 鞁犼碃鞛愲姅 歆�雮� 靹� 雼� 霃欖晥 毵る弰霅� 歃濌秾鞐� 雽�頃� 氤搓碃頃� 靷暛 鞐嗢潓鞚� 氤搓碃頄堨溂氅�, 毵る弰鞚胳澊 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 頇曥澑靹滊弰 韽暔頃橁碃 鞛堨姷雼堧嫟.
Madrigal Pharmaceuticals (MDGL) a d茅pos茅 un avis Form 144 pour la vente propos茅e de 4 100 actions ordinaires par l'interm茅diaire de Morgan Stanley Smith Barney LLC le 15/08/2025. le dossier indique une valeur de march茅 agr茅g茅e de 1 503 481,48 $ bas茅e sur la transaction et fait 茅tat de 22 289 014 actions en circulation pour l'茅metteur. Les actions ont 茅t茅 acquises et seront vendues 脿 la m锚me date suite 脿 l'exercice d'options dans le cadre d'un plan enregistr茅, le paiement ayant 茅t茅 effectu茅 en 别蝉辫猫肠别蝉. Le d茅clarant indique rien 脿 signaler concernant des titres vendus au cours des trois derniers mois et inclut l'attestation standard selon laquelle le vendeur n'est pas au courant d'informations d茅favorables importantes non divulgu茅es.
Madrigal Pharmaceuticals (MDGL) meldete eine Form 144-Mitteilung 眉ber den geplanten Verkauf von 4.100 Stammaktien 眉ber Morgan Stanley Smith Barney LLC am 15.08.2025. Die Einreichung nennt einen aggregierten Marktwert von $1.503.481,48 basierend auf der Transaktion und weist 22.289.014 ausstehende Aktien des Emittenten aus. Die Aktien wurden erworben und werden am selben Datum durch Aus眉bung von Optionen im Rahmen eines registrierten Plans verkauft; die Zahlung erfolgte in Bargeld. Der Einreicher gibt f眉r in den letzten drei Monaten verkaufte Wertpapiere nichts zu berichten an und enth盲lt die 眉bliche Versicherung, dass dem Verk盲ufer keine nicht offengelegten, wesentlichen negativen Informationen bekannt sind.
FAQ
What securities did Madrigal Pharmaceuticals (MDGL) propose to sell in the Form 144?
When is the approximate date of the proposed sale in the Form 144 for MDGL?
Through which broker is the MDGL sale being proposed?
How were the shares being sold acquired according to the filing?
Does the filing report any other securities sold in the past three months for the account?
